Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002687 · ClinicalTrials.gov registry record · Phase 1
Interleukin-2 in Treating Patients With Mycosis Fungoides
A Phase 1 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00002687 is a Phase 1 study that has completed, run by University of Washington. The registered enrollment target is 30 participants.
The verdict
NCT00002687, a Phase 1 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 in treating patients who have mycosis fungoides.
Interventions
- BIOLOGICAL aldesleukin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1995-02 |
| Est. Completion | 2003-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002687
The ClinicalTrials.gov registry entry for NCT00002687 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aldesleukin is the first listed.
NCT00002687 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002687 about?
NCT00002687 is a clinical study titled "Interleukin-2 in Treating Patients With Mycosis Fungoides". RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 in treating patients who have mycosis fungoides.
What is the current status of trial NCT00002687?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 1995-02. Estimated completion is 2003-07.
What interventions are being tested in trial NCT00002687?
The interventions under investigation include: aldesleukin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002687?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.